Condition: Fatigue Related to Cancer Treatment · Breast Cancer · Sponsor: Natureceuticals Sdn Bhd
The goal of this clinical trial is to evaluate whether Nuvastatic 300 mg capsules can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy. The main questions it aims to answer are: * Does Nuvastatic 300 mg capsules significantly reduce cancer-related fatigue compared to placebo? * Is Nuvastatic 300 mg capsules safe and well tolerated in this patient population? Researchers will compare Nuvastatic 300 mg capsules vs placebo to see if Nuvastatic 300 capsule improves fatigue scores and maintains an acceptable safety profile. Participants will: * Receive Nuvastatic 300 mg capsules or placebo capsules (3 times per day) for 3 cycles of 20 days each (total \~60 treatment days). * Continue their standard first-line chemotherapy regimen. * Provide blood sample assessments at Screening and End of Treatment. * Complete patient diaries and fatigue assessments as per protocol.
This description comes directly from the study's public registry record.
Aman Shah Abdul Majid, MBChB, DPhil · +605-2490500 · amanharvard2020@outlook.com
Always discuss trial participation with your own doctor first.
| Omega Hospital Chinna Gadhili | Visakhapatnam, Andhra Pradesh, India | Recruiting |
| K R Hospital | Mysore, Karnataka, India | Active Not Recruiting |
| Jeevanjyoti Cancer Hospital | Jalgaon, Maharashtra, India | Active Not Recruiting |
| Sangavi Multispeciality Hospital Pvt. Ltd, | Pune, Mahrasta, India | Recruiting |
| Erode Cancer Care Centre | Erode, Tamil Nadu, India | Recruiting |
| International Oncology Cancer Tower 1 | Kanpur, Uttar Pradesh, India | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07669467